AbCellera Biologics Inc.
ABCLHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, AbCellera Biologics Inc. (ABCL) is listed under Biotechnology. At a $3.83B market cap, AbCellera Biologics Inc. ranks as a mid-cap company within healthcare. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis.
Market Cap
$3.83B
Beta
1.41
P/E (TTM)
—
P/E (Fwd)
-15.50
EPS (TTM)
$-0.54
EPS (Fwd)
$-0.76
ROE
-17.3%
ROA
-10.4%
Cash
$540.1M
Total Debt
$135.6M
Free CF
-$46.4M
52W Change
104.8%
Annual Financials
Cash vs Debt
Where ABCL stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, ABCL finished 60.78% above its 150-day moving average ($7.42) and 84.10% above its 200-day moving average ($6.48). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ABCL overbought or oversold?
At the October 20, 2026 close, ABCL's RSI(14) was 21.6, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
AbCellera Biologics Inc. holds $540.1M in cash against $135.6M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$46.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -17.3%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $485.4M (2022) to $75.1M (2025), a 85% decline worth watching.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence AbCellera Biologics Inc.'s trajectory.